Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Fig. 2

Comparison of time to progression with trabectedin (TTP2) versus time to progression with prior therapy (TTP1) for the 11 patients. The growth modulation index (GMI) is the ratio between TTP2 and TTP1. Two patients did not progress under trabectedin (patient 1 and patient 5), so that only a minimum predictive GMI could be estimated. All in all, seven patients had a GMI (effective or predictive) > 1.33 (63.6 %, 95 % CI = [30.8–89.1 %])

Back to article page